Under the ERC Starting Grant ERC-2014-StG – 637830 "Novel Asthma Therapy" we are developing dry powder platform technologies for pulmonary delivery of siRNA for targeting activated T cells in the lung.
Our project has a clear potential of advancing pulmonary nanomedicine as novel asthma therapy.
- Daniel P Feldmann et al., In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. Journal of Controlled Release 2018, 276, 50-58
- Daniel P. Feldmann et al., The impact of microfluidic mixing of triblock micelleplexes on in vitro/in vivo gene silencing and intracellular trafficking, Nanotechnology 2017, 28(22), 224001.
- Yuran Xie et al., Targeted Delivery of siRNA to Transferrin Receptor Overexpressing Tumor Cells via Peptide Modified Polyethylenimine, Molecules 2016, 21(10), 1334.
- Yuran Xie et al., Targeted Delivery of siRNA to Activated T Cells via Transferrin-Polyethylenimine (Tf-PEI) as a Potential Therapy of Asthma, Journal of Controlled Release, 2016, 229, 120-9.
- Yuran Xie and Olivia Merkel, Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma, Archiv der Pharmazie 2015, 348 (19), 681-688.